All SEC Filings
Corporate Changes & Voting Matters
Periodic Financial Reports
Proxy Statements
Tender Offer/Acquisition Reports
Offering Registrations
- Pfizer (PFE) Ascends While Market Falls: Some Facts to Note In the most recent trading session, Pfizer (PFE) closed at $28.39, indicating a +0.32% shift from the previous trading day.
Zacks • 5 hours ago
PFE +0.32% -
- Pfizer's Stock Turnaround Stalls On Covid/Flu Misstep — Is It A Buy Or A Sell? Pfizer stock slipped close to a sell zone after its Covid/flu vaccine missed the mark in final-phase testing. Is PFE stock a buy or a sell?
- Acepodia collaborates with Pfizer to advance antibody-cell conjugation therapies Pfizer Ignite will support Acepodia in developing its pipeline cancer therapeutic candidates.
Pharmaceutical Technology • 11 hours ago
PFE +0.32% - Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.
Zacks • 11 hours ago
PCVX PFE +0.32% -
Zacks • 12 hours ago
LLY PFE +0.32% ROG.SW -
- With 67% ownership, Pfizer Inc. (NYSE:PFE) boasts of strong institutional backing Key Insights Institutions' substantial holdings in Pfizer implies that they have significant influence over the...
Simply Wall St. • 13 hours ago
PFE +0.32% - Is Pfizer Inc. (PFE) the Best Cancer Stock to Buy Now? We recently compiled a list of the 10 Best Cancer Stocks To Buy Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other cancer stocks. Global Oncology Market Overview and Drug Shortages In 2022, the global oncology market was valued at approximately $203.42 billion and is […]
Insider Monkey • 23 hours ago
PFE +0.32% - Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market Vaxcyte shares rocketed Tuesday after the biotech company delivered "stunning" test results for its pneumococcal vaccine.
Investor's Business Daily • yesterday
PCVX PFE +0.32% - Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study Tuesday, Valneva SE (NASDAQ:VALN) and Pfizer Inc. (NYSE:PFE) released immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose. One month after receiving the second booster dose, the immune response and safety profile of VLA15 were similar to those reported after receiving the first booster dose, showing compatibility with the anticipated benefit o
Benzinga • yesterday
PFE +0.32% VLA.PA -
- Heard on the Street: Pfizer Better Watch Out for This Biotech Merck has introduced a strong competitor. Vaxcyte reported positive data for a vaccine that protects against more strains, creating a formidable challenge for the big pharma incumbents. On Tuesday, Vaxcyte announced that a mid-stage study of its vaccine showed robust immune responses for all 31 serotypes at all doses studied.
The Wall Street Journal • yesterday
PCVX PFE +0.32% MRK -0.67% - Biotech Startup Vaxcyte Is a Threat to Pfizer and Merck. A Vaccine Candidate Is Why. At the highest dose tested, Vaxcyte’s shot elicited a stronger immune response against 18 of the 20 strains compared with Pfizer’s.
Barrons.com • yesterday
PFE +0.32% PCVX - Vaxcyte's shares hit record high after early data on pneumococcal vaccine Vaxcyte said some doses of vaccine VAX-31 showed immune responses that exceeded expectations for 20 serotypes, or variations of the pneumococcal bacteria, which it had in common with Pfizer's Prevnar 20 vaccine. Pneumococcal disease is a serious bacterial infection caused by bacteria called streptococcus pneumoniae.
Reuters • yesterday
PCVX PFE +0.32% - Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.
Zacks • yesterday
VLA.PA PFE +0.32% BSX -
- Vaxcyte’s “best-case” data for pneumococcal vaccine boost shares The company's value jumped by several billion dollars as trial results showed its experimental shot could match and, in some cases, even outperform Pfizer's market-leading Prevnar 20.
BioPharma Dive • yesterday
PCVX PFE +0.32% MRK -0.67% - Valneva and Pfizer report positive data from trial of Lyme disease vaccine booster VLA15’s safety profile after the second booster was similar to that of the first dose, with no safety concerns reported.
Clinical Trials Arena • yesterday
PFE +0.32% VLA.PA - Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.
Zacks • 2 days ago
NVAX PFE +0.32% MRNA - Novavax wins FDA emergency approval for updated Covid-19 vaccine The US regulatory agency has also approved updated versions of Moderna and Pfizer / BioNTech’s Covid-19 vaccines in the past two weeks.
Pharmaceutical Technology • 2 days ago
NVAX PFE +0.32% MRNA -
- Pfizer. Inc. (PFE): One of the Best Affordable Stocks Under $40 According to Short Sellers We recently compiled a list of the 10 Best Affordable Stocks Under $40 According to Short Sellers. In this article, we are going to take a look at where Pfizer. Inc. (NYSE:PFE) stands against the other affordable stocks under $40. Several traders tend to profit from stocks through appreciation. However, some do the opposite– their idea […]
Insider Monkey • 5 days ago
PFE +0.32% ^GSPC - Why IBD 50's Alnylam Just Reversed Its 50% Gain — And BridgeBio Surged Alnylam stock tumbled Friday after the company's Pfizer-rivaling heart disease treatment lagged expectations in a lengthy study.
Investor's Business Daily • 5 days ago
ALNY PFE +0.32% - US clears updated COVID shots from Novavax, adding a 3rd fall vaccine option U.S. regulators have cleared a third updated COVID-19 vaccine for this fall, shots made by Novavax Inc. Already, Pfizer and Moderna are shipping shots modified to better match more recent strains of the ever-evolving coronavirus. Friday, the Food and Drug Administration gave the OK to the updated Novavax formula, too — and those shots are open to anyone 12 and older.
Associated Press Finance • 5 days ago
NVAX PFE +0.32% MRNA
Performance Overview
Trailing total returns as of 9/4/2024, which may include dividends or other distributions. Benchmark is S&P 500
| Return | PFE | S&P 500 |
|---|---|---|
| YTD | +3.04% | +15.73% |
| 1-Year | -15.97% | +22.24% |
| 3-Year | -31.04% | +21.71% |
